Diabetic Peripheral Neuropathy R&D Pipeline Analysis Report, Q4 2020
Diabetic Peripheral Neuropathy Pipeline Overview
The Q4 Diabetic Peripheral Neuropathy pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under development for Diabetic Peripheral Neuropathy, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Diabetic Peripheral Neuropathy Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Diabetic Peripheral Neuropathy disease overview, Diabetic Peripheral Neuropathy types, Diabetic Peripheral Neuropathy symptoms, causes, and FDA/EMA approved treatment options.
Diabetic Peripheral Neuropathy Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Diabetic Peripheral Neuropathy indication. The report presents near-term and long-term pipeline development trends and potential insights.
Diabetic Peripheral Neuropathy Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 23 companies. Business profiles and contact details of the companies actively perusing Diabetic Peripheral Neuropathy pipeline are assessed.
Diabetic Peripheral Neuropathy R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Diabetic Peripheral Neuropathy discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Diabetic Peripheral Neuropathy companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Diabetic Peripheral Neuropathy pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Diabetic Peripheral Neuropathy Pipeline Market News and Developments during 2020
The Diabetic Peripheral Neuropathy industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Diabetic Peripheral Neuropathy Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Diabetic Peripheral Neuropathy pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under development for Diabetic Peripheral Neuropathy, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Diabetic Peripheral Neuropathy Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Diabetic Peripheral Neuropathy disease overview, Diabetic Peripheral Neuropathy types, Diabetic Peripheral Neuropathy symptoms, causes, and FDA/EMA approved treatment options.
Diabetic Peripheral Neuropathy Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Diabetic Peripheral Neuropathy indication. The report presents near-term and long-term pipeline development trends and potential insights.
Diabetic Peripheral Neuropathy Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 23 companies. Business profiles and contact details of the companies actively perusing Diabetic Peripheral Neuropathy pipeline are assessed.
Diabetic Peripheral Neuropathy R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Diabetic Peripheral Neuropathy discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Diabetic Peripheral Neuropathy companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Diabetic Peripheral Neuropathy pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Diabetic Peripheral Neuropathy Pipeline Market News and Developments during 2020
The Diabetic Peripheral Neuropathy industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Diabetic Peripheral Neuropathy Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Diabetic Peripheral Neuropathy pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 23 companies are included including Achelios Therapeutics Inc, Applied Therapeutics Inc, Bionevia Pharmaceuticals, Bristol-Myers Squibb Co, Calchan Ltd, Celularity Inc, Commence Bio Inc, CSPC Pharmaceutical Group Ltd, Eli Lilly and Co, Exodos Life Sciences Limited, GNT Pharma Co Ltd, Grunenthal GmbH, Immune Pharmaceuticals In, Ion Channel Pharmacology LLC, Korea United Pharm Inc, Mitsubishi Tanabe Pharma Corp, Pfizer Inc, Praetego Inc, Reata Pharmaceuticals Inc, Seneca Biopharma Inc, Sonnet BioTherapeutics Holdings Inc, Sphaera Pharma Pte Ltd, Winsantor Inc,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Diabetic Peripheral Neuropathy pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. DIABETIC PERIPHERAL NEUROPATHY PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Diabetic Peripheral Neuropathy Pipeline, 2020
2.2 Most focused Mechanism of Action in Diabetic Peripheral Neuropathy Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Diabetic Peripheral Neuropathy pipeline
2.5 Active Companies Developing Diabetic Peripheral Neuropathy pipeline
3. DIABETIC PERIPHERAL NEUROPATHY DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. DIABETIC PERIPHERAL NEUROPATHY PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Achelios Therapeutics Inc
Applied Therapeutics Inc
Bionevia Pharmaceuticals
Bristol-Myers Squibb Co
Calchan Ltd
Celularity Inc
Commence Bio Inc
CSPC Pharmaceutical Group Ltd
Eli Lilly and Co
Exodos Life Sciences Limited
GNT Pharma Co Ltd
Grunenthal GmbH
Immune Pharmaceuticals In
Ion Channel Pharmacology LLC
Korea United Pharm Inc
Mitsubishi Tanabe Pharma Corp
Pfizer Inc
Praetego Inc
Reata Pharmaceuticals Inc
Seneca Biopharma Inc
Sonnet BioTherapeutics Holdings Inc
Sphaera Pharma Pte Ltd
Winsantor Inc
5. DIABETIC PERIPHERAL NEUROPATHY PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. DIABETIC PERIPHERAL NEUROPATHY PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. DIABETIC PERIPHERAL NEUROPATHY PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Diabetic Peripheral Neuropathy Pipeline, 2020
2.2 Most focused Mechanism of Action in Diabetic Peripheral Neuropathy Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Diabetic Peripheral Neuropathy pipeline
2.5 Active Companies Developing Diabetic Peripheral Neuropathy pipeline
3. DIABETIC PERIPHERAL NEUROPATHY DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. DIABETIC PERIPHERAL NEUROPATHY PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Achelios Therapeutics Inc
Applied Therapeutics Inc
Bionevia Pharmaceuticals
Bristol-Myers Squibb Co
Calchan Ltd
Celularity Inc
Commence Bio Inc
CSPC Pharmaceutical Group Ltd
Eli Lilly and Co
Exodos Life Sciences Limited
GNT Pharma Co Ltd
Grunenthal GmbH
Immune Pharmaceuticals In
Ion Channel Pharmacology LLC
Korea United Pharm Inc
Mitsubishi Tanabe Pharma Corp
Pfizer Inc
Praetego Inc
Reata Pharmaceuticals Inc
Seneca Biopharma Inc
Sonnet BioTherapeutics Holdings Inc
Sphaera Pharma Pte Ltd
Winsantor Inc
5. DIABETIC PERIPHERAL NEUROPATHY PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. DIABETIC PERIPHERAL NEUROPATHY PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
